Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.58 |
| ▸ | DHFR | P00374 | 4/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12814361 | 0.84 | HRH4 (0.58) | HRH4DHFRDCPS | |
| SCHEMBL9433928 | 0.84 | LMNA (0.47) | HRH4ADORA2A | |
| SCHEMBL15450912 | 0.84 | ALDH1A1 (0.60) | HRH4ADORA2AHSP90AA1 | |
| SCHEMBL3245979 | 0.81 | ADORA2A (0.51) | HRH4ADORA2AHSP90AA1 | |
| SCHEMBL3778992 | 0.81 | HTT (0.64) | HRH4ADORA2A | |
| SCHEMBL13982551 | 0.81 | LMNA (0.45) | HRH4ADORA2AHSP90AA1 | |
| Quinazoline-2,4,6-Triamine SCHEMBL335027 | 0.79 | DCPS (0.57) | DHFRDCPS | |
| Quinazoline-2,4,6-Triamine SCHEMBL30050079 | 0.79 | DCPS (0.57) | DHFRDCPS | |
| SCHEMBL861205 | 0.77 | CYP1A1 (0.50) | HRH4ADORA2ADCPSHSP90AA1 | |
| SCHEMBL25367735 | 0.77 | F2R (0.56) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1062209-B1 | METABOLICALLY INERT ANTI-INFLAMMATORY AND ANTI-TUMOR ANTIFOLATES | NAIR MADHAVAN G (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2004072102-A2 | BENZENE ACETAMIDE COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004045500-A2 | PROCESS FOR SYNTHESIZING ANTIFOLATES | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040092739-A1 | Process for synthesizing antifolates | BIONUMERIK PHARMACEUTICALS, INC. | 2004-05-13 | — | — | US | disclosed |
| US-4048312-A | 2,4-Diaminoquinazolines as antithrombotic agents | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-3956495-A | 2,4-Diaminoquinazolines as antithrombotic agents | ELI LILLY AND COMPANY (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092739-A1 | Process for synthesizing antifolates | DHFR, FDPS, MTHFD2 | HRH4 3036/4885DHFR 1/4885ADORA2A 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.